IDH1R132H抗体在测定人脑胶质瘤中IDH1突变的意义  

Significance of detecting IDH1 mutations in glioma with IDH1R132H anti-body

作　　者：王君祥[1] 褚荣涛[1] 周幽心[2] 冯鸣[2] 苏作鹏[2] 

机构地区：[1]常熟市第二人民医院神经外科,215500 [2]苏州大学附属第一医院神经外科暨脑神经实验室

出　　处：《临床神经外科杂志》2012年第5期262-265,共4页Journal of Clinical Neurosurgery

摘　　要：目的研究IDH1R132H抗体(IMab-1)在测定人脑胶质瘤中IDH1突变中的作用。方法使用IDH1R132H抗体,通过免疫组织化学及Western-Blot方法检测97例人脑胶质瘤及9例其他中枢神经系统肿瘤,10例对照组脑组织的IDH1突变情况,比较其与采用基因片段测序方法检测结果的差异。结果 IDH1基因阳性测定结果:免疫组织化学方法为46例,Western-blot方法为49例,基因片段测序方法为52例,三者在统计学上无差异性。结论使用IDH1R132H抗体,通过免疫组织化学及Western-Blot方法检测人脑胶质瘤中IDH1突变情况,虽然有一定的假阴性,但准确率较高,操作方便,为一种便捷良好的检测IDH1突变的方法。Objective To investigate the significance of IDH1R132H Anti-body （ IMab-1 ） in detecting IDH1 mutations in human gliomas. Methods Immunohistochemistry and Western-blot analysis were used in detecting IDH1 mutations in human gliomas with IDH1R132H Anti-body; compare the difference of IDH1 mutations detected by IDH1R132H Anti-body with that by DNA direct sequence. Results Positive results of IDH1 mutations in 46 cases detected by immunohistochemistry,49 by Western-blot analysis and 52 by DNA direct sequence. There is no statistical difference in detecting IDH1 mutations by three methods. Conclusions Although detecting IDH1 mutations in glioma by immunohistochemistry and Western-blot with IDH1R132H antibody has false negative findings, the superiority of this method manifests as high accuracy and convenient operation . It＇s a good method to detect IDH1 mutations with IDH1R132H antibody.

关 键 词：胶质瘤 异柠檬酸脱氢酶同工酶1 基因 抗体 

分 类 号：R739.4[医药卫生—肿瘤]